about
Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in HumansRupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study.Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres.Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity ratesRandomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure.Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans.A bioavailability/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation.Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials.Stress assessment based on EEG univariate features and functional connectivity measures.Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers.Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form.Pharmacodynamics assessment of Bemiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volunteers and in subjects with varying degrees of renal impairmentPharmacology of ayahuasca administered in two repeated doses
P50
Q27300685-C3F6D3C9-ED85-4BB2-A91E-866C2F09543AQ30475256-5458FCA8-0F5B-431B-B7DA-CD9DB7E90C8DQ35211679-4280C547-13C3-43F1-BDDF-DB9D6DA4DAE5Q35922955-5C8E6EB1-E3B4-4A70-AB85-9659AC599AA1Q35940064-A93FC9FD-540D-41D3-995F-DD730ED70F88Q36363810-2C81B881-BFC0-4210-8C6F-E7FAB5AF15F8Q43293152-DE15BCCA-CF20-4880-A7CC-F0E6B8FD2161Q47933632-BA9D67B5-4B11-4157-B424-E9E6AB039746Q47970065-5EE90B15-6A70-4192-A3A2-7BD9CB58F707Q48218312-8B677012-115D-487C-8293-F74C6E2C8E6CQ51298914-B76E262D-1097-46D2-A968-143C891ECF98Q60619528-71538796-4E2B-4251-A183-C35A6267FD74Q84765576-F3C56978-6FE5-4588-9014-77B814687FC6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
María Rosa Ballester
@ast
María Rosa Ballester
@en
María Rosa Ballester
@es
María Rosa Ballester
@nl
type
label
María Rosa Ballester
@ast
María Rosa Ballester
@en
María Rosa Ballester
@es
María Rosa Ballester
@nl
prefLabel
María Rosa Ballester
@ast
María Rosa Ballester
@en
María Rosa Ballester
@es
María Rosa Ballester
@nl
P106
P31
P496
0000-0002-0472-9558